Insight Database shows that in the first half of 2026, there were in ChinaOver 700 New DrugsProgress has shifted. Among these, 61 new drugs received regulatory approval for the first time, 59 new drugs have submitted marketing applications, and an additional 84 new drugs have advanced to Phase III clinical trials.
From the perspective of R&D institutions, Hengrui Pharma continues to hold the top spot in domestic new drug development progress, with 30 new drugs showing changes in their development status in the first half of this year. Additionally, other companies that successfully made it into the top ten includeCSPC, Sino Biopharmaceutical, Qilu Pharmaceutical, AstraZeneca,3SBio,Haisco Pharmaceutical,Fosun Pharma,Hansoh Pharma,Changchun High-Tech and Innovent Biologics。
Data Description: Includes subsidiaries; sourced from the Domestic Project Progress module of the DXY Insight database, filtered for "Current Project Progress" ≥ Phase I clinical trials."Current Progress Timeline"For the period from January 1, 2026 to June 30, 2026,"New Drug Type"New chemical drugs and new biological products: Early-stage clinical development = Phase I + Phase I/II; Late-stage clinical development = Phase II, Phase II/III, Phase III; Marketing approval = Approved for marketing + Application for marketing approval; Excluding localization of original research drugs.This article briefly introduces the pipeline highlights of the top ten pharmaceutical companies for readers' reference.As one of the leading innovative pharmaceutical companies in China, Hengrui Pharma is continuously expanding into autoimmune, metabolic, cardiovascular, and respiratory therapeutic areas while consolidating its advantages in oncology.Chronic Diseases and High-Incidence DiseasesDomain Expansion.In the first half of this year, Hengrui Pharma has30 New DrugsProgress has changed, with indications covering non-small cell lung cancer, hyperlipidemia, systemic lupus erythematosus, and diabetes.diseases, obesity, etc. Among them, 2 were approved for marketing for the first timeproducts, namelyNew Drug for Hyperuricemia: LuZinorena, andGastric CancerNew DrugRilafup-α。Source: DXY Insight DatabaseAdditionallyIn addition, Hengrui Pharma also submitted marketing applications for four new drugs.respectivelyCFBSuppressPreparationDosage formLikangkepan、ANGPTL3 Monoclonal AntibodySHR-1918、GLP1R/INSRDual-Target Combination FormulationHR17031 and the CASR inhibitor SHR-6508.In the first half of this year, CSPC’s innovative pipeline witnessed explosive progress, achieving three out-licensing deals and seeing updates in the development status of 20 new drugs, covering various therapeutic modalities such as siRNA, ADCs, and mRNA vaccines.Among these new drugs, one received its initial marketing approval, namely Anituo monoclonal antibody. Anituo monoclonal antibody is a domesticThe First Domestically Produced HER2 Bispecific Antibody to Enter the Market, initially developed by Alphamab Oncology, with CSPC acquiring the rights for its development and commercialization in mainland China in August 2021.In addition, three new drugs have advanced to Phase III clinical trials, including those targeting VEGFR and CSF1R.SYHA1813, the PCSK9-targeting siRNA therapy SYH2053, and the TSLP monoclonal antibody CM236.CSPC Pharmaceutical GroupOver the past two years, China Biopharm has significantly enriched its pipeline through transactions and mergers and acquisitions. Currently, it has over 100 new drugs in development, covering therapeutic modalities such as antibodies, antibody-drug conjugates (ADCs), small interfering RNA (siRNA), and proteolysis-targeting chimeras (PROTACs).In the first half of this year, ChinaChina Biopharmaceuticals Co.16 New DrugsProgress has changed, with one product receiving its initial market approval, namelyOral Small-Molecule JAK/ROCK Inhibitor: Rofacitinib. It is worth noting that in March 2026, the global development and commercialization rights for this product were licensed to Sanofi, in a deal totaling $1.53 billion.Meanwhile, China Biopharmaceuticals submitted marketing applications for three new drugs, including a CLDN-18.2 ADC, a CD3/EPCAM bispecific antibody, and a third-generation EGFR TKI, for the treatment of gastric cancer, malignant pleural and ascitic effusions, and non-small cell lung cancer, respectively.Source: DXY Insight DatabaseQilu Pharmaceutical has been intensifying its innovation-driven transformation, with R&D investment reaching RMB 5.37 billion in 2025, accounting for 14.5% of total revenue. This high-intensity, sustained R&D investment is gradually translating into a dense output of innovative achievements.In the first half of 2026, Qilu Pharmaceutical saw changes in the development progress of 13 new drugs, among whichSeven candidates are entering clinical trials for the first time., including the CD2/CD3/PSMA trispecific antibody QLF4113 with first-in-class (FIC) potential.Furthermore,This March,Qilu Pharmaceutical’s PCSK9 siRNA therapy RBD7022, licensed from Ruibo Biologics, has also advanced to Phase III clinical trials for the indication of hyperlipidemia.AstraZeneca isUniqueMultinational pharmaceutical companies ranking among the top ten in domestic new drug progress. As the performance leader of MNCs in China, AstraZeneca had in China during the first half of the year11 New DrugsProgress has changed. Among them, two products have been approved for market launch, both of which are monoclonal antibody products.In March this year, tezepelumab was approved for the treatment of asthma and chronic rhinosinusitis with nasal polyps. In the same yearIn April, curmlimab secured two additional indications in succession, for use in combination with durvalumab as first-line treatment for non-small cell lung cancer and liver cancer, respectively.Notably, AstraZeneca has also advanced its first dual-target CAR-T therapy, AZD0120, into Phase III clinical trials for the indication of multiple myeloma.3SBio has demonstrated its innovative capabilities through a major business development deal with Pfizer. In the first half of this year, it had 1 in China0 new drugs have seen changes in their development progress, among which 2 were approved for marketing for the first time, includingRoxadustat α,Anmucitumab。
Specifically, Roxadustat Alpha is a cytokine drug primarily used for the treatment of chronic renal anemia in patients dependent on hemodialysis.Blood. Anmukitab is an IL-17A monoclonal antibody that has been approved for the treatment of moderate-to-severe plaque psoriasis in adults.In February 2026, 3SBio also submittedAMarketing Application for IL-4Rα Monoclonal Antibody, with Indications forModerate to Severe Atopic Dermatitis Suitable for Systemic Therapyitis. In the early clinical stages, 3SBio has laid out five global first-in-class (FIC) products.
Source: DXY Insight DatabaseHaisco’s innovative pipeline is beginning to enter the harvest phase. In the first half of this year, Haisco successively secured4 Major BD Deals, with a cumulative total transaction value exceeding USD 6 billion, involving multiple novel small-molecule drugs such as PDE inhibitors, Nav1.8 inhibitors, and CFB inhibitors.Source: DXY Insight DatabaseIn addition to achieving breakthroughs in overseas expansion, Haisco Pharmaceutical has also begun to accelerate the advancement of its new drug pipeline. In the first half of this year, it had10 ProductsThere have been changes in the progress of new drugs, among which the CFB inhibitor HSK39297 has submitted a marketing application, THRB inhibitor HSK31679, PDE3/4 inhibitor HSK39004, and PDE4B inhibitor HSK44459 have initiated Phase III clinical trials.
In the first half of 2026, Fosun Pharma had10 ProductsChanges in New Drug Progress, Overall ShowingAccelerating the Launch of Key Products, Highly Innovative Early-Stage Pipelinecharacteristics.This February, JinHong, a subsidiary of Fosun PharmaPharmaceutical DevelopmentThe marketing application for the Class 1 novel drug motomidate hydrochloride, indicated for anesthesia induction and short-duration surgical anesthesia, has been accepted by the CDE. Meanwhile, HLX43, a PDL1 ADC novel drug in-licensed from Yilian Biologics by the company, has also entered Phase II/III clinical trials.Early-stage products have also seen considerable progress, such asBCMA/CD19 Dual-Target CAR-TTherapy FKC289 has initiated Phase I/II clinical trials for autoimmune diseases such as primary membranous nephropathy, while the EGFR/c-Met bispecific antibody-drug conjugate (ADC) HLX48 and the CD3/CD28/DLL3 trispecific antibody HLX3901 have entered clinical development for the first time.In the first half of 2026, HansohPharmaceuticals have10 VarietiesNew drug development progress has shifted, with a primary focus on oncology, cardiovascular and metabolic diseases, and neuroscience.Among these advancing new drugs, three have submitted marketing applications, namely:GLP-1R/GIPR agonist orforglipron, c-Met inhibitor damalitinib, and CASR agonist SHR-6508. Notably,Orforglipron was also licensed to Regeneron this June, with the total transaction value reaching$2.01 billion. AndSHR-6508 was licensed in by Hansoh from Hengrui Pharma at the end of last year.Source: DXY Insight DatabaseAdditionally, Hansoh Pharma has also targeted the insomnia therapeutic area, advancing its OX2R antagonist HS-10506 into Phase III clinical trials.Changchun High-Tech, the leader in growth hormone, has now expanded its pipeline into oncology and autoimmune diseases. The Insight database shows that Changchun High-Tech currently has over 100 innovative products in development, covering various drug types such as antibodies, siRNA, ADCs, mRNA, and molecular glue degraders.Source: DXY Insight DatabaseIn the first half of this year, Changchun High-Tech had9 ProductsNew drug development progress has changed, with 7 candidates from GeneScience Pharmaceuticals and 2 from BCHT. The faster-progressing ones are PD-1 inhibitors.Agonist monoclonal antibodyGenSci120 initiated Phase II clinical trials for moderate-to-severe rheumatoid arthritis in February this year.Innovent Biologics has completed its transition from a biotechThe Leap into Biopharma. In 2025, the company's product revenue reached RMB 11.9 billion, surpassing the RMB 10 billion mark for the first time and turning a profit after losses.In the first half of this year, Innovent successively partnered withEli Lilly, PfizerSecured a major BD deal, with a total value approaching $20 billion, covering only the upfront paymentamounting to USD 1 billion. In terms of pipeline, progress is equally rapid, with9 ModelsChanges in the progress of new drugs, involving bispecific antibodies, trispecific antibodies, ADCs, and bispecific antibody ADCs.Specifically, in June this year, Innovent submitted the marketing application for IBI363 to the CDE. This isThe World’s First CLDN18.2 ADC Submitted for Marketing ApprovalIn addition, Innovent has initiated Phase III clinical trials for two new drugs, including the BCMA/CD3/GPRC5D trispecific antibody IBI3003 and the XO inhibitor teguxostat.Cover Source:Corporate Logo / Zcool HellowDisclaimer:This article is for informational purposes only and does not represent the positions or views of Insight, nor does it constitute recommendations or introductions to treatment plans. If needed, please consult and contact legitimate medical institutions.
